Stock Events

Stock Events

Adicet Bio 

0
56
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 18
€0.06
Jun 18
€0.06
Mar 18
€0.37
Dec 17
€0.38
Sep 17
€0.38
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

11NovExpected
Q1 2026
Q2 2026
Next
-2.63
-2.21
-1.79
-1.37
Expected EPS
-1.36614631384
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-101.45MNet Income

Analyst Ratings

34.40Average Price Target
The highest estimate is 68.29.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1IJ.STU. It's not an investment recommendation.
Amazon
7
AMZN
Pfizer
7
PFE
Ares Capital
7
ARCC
Apple
6
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap297.15M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, similar to Adicet Bio's focus on cell therapies for cancer, making them direct competitors in the cell therapy space.
Allogene Therapeutics
ALLO
Mkt Cap680.62M
Allogene Therapeutics operates in the field of allogeneic CAR T cell therapies, directly competing with Adicet Bio's allogeneic cell therapy approach for treating cancer.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is engaged in gene editing and CAR-T therapy developments, competing in the innovative therapy space including cancer treatments, overlapping with Adicet Bio's focus areas.
Novartis
NVS
Mkt Cap304.1B
Novartis is a large pharmaceutical company with a strong presence in the cell therapy market, including Kymriah, a CAR-T therapy for cancer, making it a competitor to Adicet Bio.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T therapy for cancer, directly competing with Adicet Bio's cell therapy approaches.
Precigen
PGEN
Mkt Cap2.54B
Precigen is a biotechnology company that develops gene and cell therapies, including CAR-T therapies for cancer, making it a competitor in the same field as Adicet Bio.

About

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Show more...
CEO
Chen Schor
Employees
102
Country
United States
ISIN
US0070022076
WKN
000A41X5V

Listings

STU
DE
1IJ.STU
F
DE
1IJ.F
MU
DE
1IJ.MU
LSE
GB
0HX7.LSE

0 Comments

Share your thoughts

FAQ

What is Adicet Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Adicet Bio stocks are traded under the ticker 1IJ.STU.
When is the next Adicet Bio earnings date?▼
Adicet Bio is going to release the next earnings report on November 11, 2026.
What were Adicet Bio earnings last quarter?▼
1IJ.STU earnings for the last quarter are -1.72 EUR per share, whereas the estimation was -1.46 EUR resulting in a -17.61% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Adicet Bio revenue for the last year?▼
Adicet Bio revenue for the last year amounts to 0 EUR.
What is Adicet Bio net income for the last year?▼
1IJ.STU net income for the last year is -101.45M EUR.
Does Adicet Bio pay dividends?▼
Yes, 1IJ.STU dividends are paid quarterly. The last dividend per share was 0.06 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Adicet Bio have?▼
As of September 09, 2026, the company has 102 employees.
In which sector is Adicet Bio located?▼
Adicet Bio operates in the Health & Wellness sector.
When did Adicet Bio complete a stock split?▼
The last stock split for Adicet Bio was on December 30, 2025 with a ratio of 1:16.
Where is Adicet Bio headquartered?▼
Adicet Bio is headquartered in BOSTON, United States.